Cereton

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cereton

Quick Facts

Property Description
Active ingredient Choline alfoscerate (α-GPC)
Form Soft gelatin capsules and Solution for injection
Pharmacological class Central Cholinomimetic (N07AX02)
Common use Cognitive support, Neuroprotection
Origin Semi-synthetic (phospholipid derivative)

The Core Identity of Cereton: Classification and Type

Cereton is a prescription-only medicine whose active substance, Choline alfoscerate (INN), belongs to the group of Other Parasympathomimetics. This places it within the broader group of agents intended to support central nervous system function. Cereton is also recognized pharmacologically as both a Nootropic agent and a Neuroprotector. This medication is clinically recognized for its targeted action within the central nervous system. It is available in two main formats: soft gelatin capsules for oral use, and a sterile solution for injection in ampoules for parenteral administration, providing medical versatility.

Choline alfoscerate: Composition and Origin

The single active ingredient is Choline alfoscerate, also known as L-alpha-glycerylphosphorylcholine (α-GPC). This compound is a semi-synthetic derivative that is structurally identical to a naturally occurring choline compound found in the brain. Choline alfoscerate is a distinctive compound because its structure is designed for efficient delivery across the blood-brain barrier. It functions as an immediate neurotransmitter precursor and a phospholipid precursor, distinguishing its composition from simpler choline forms. The active compound is used as a medicine to improve cognitive function associated with neurological conditions.

The General Purpose of Cereton: Dual Neuro-Support

The general purpose of Cereton is to provide support and stabilization to neurological function through a distinct dual action mechanism. The substance acts as a Choline donor, which is critical for the synthesis of the neurotransmitter acetylcholine. Concurrently, its glycerophosphate component serves as a phospholipid precursor. Choline alfoscerate is intended to support memory and cognitive recovery in various neurodegenerative and vascular conditions. This demonstrates its intended general benefit in protecting and maintaining the structural integrity of nerve cell membranes and enhancing brain communication capacity.

Regulatory References

  1. Systematic Review on Alpha-GPC for Cognitive Dysfunctions (NIH/PubMed Central)
  2. NIH/PubMed Central article on Choline supplements and cognitive function

What side effects are possible with Cereton?

Possible Side Effects and Safety Information

The safety profile of Choline alfoscerate (Cereton) is defined by officially documented adverse reactions that are generally non-serious and infrequent, primarily involving two major system-organ classes.


Officially Documented Adverse Reactions

The adverse reactions listed in regulatory documents are typically classified by frequency. Common regulatory classification indicates effects are generally Uncommon or Rare.

System-Organ Class Officially Listed Adverse Reactions
Gastrointestinal Disorders Nausea, Vomiting, Diarrhea
Nervous System Disorders Headache
Psychiatric Disorders Insomnia
Immune System Disorders Allergic reactions

Regulatory safety information notes that the occurrence of Nausea is often transient and may be associated with the start of treatment or when the medicine is used at higher doses. All listed effects are generally described as minor and self-limiting.


Population-Specific Safety Considerations

The official labeling mandates specific safety constraints for certain populations due to insufficient regulatory data:

  • Pregnancy and Breastfeeding: The use of Choline alfoscerate is not recommended or contraindicated in women who are pregnant or breastfeeding, as safety and efficacy data are not adequate for these groups.
  • Pediatric Use: Safety and efficacy have not been established in children and adolescents.

Use of the medicine is contraindicated in individuals with known hypersensitivity to the active substance, Choline alfoscerate, or any of the product's excipients. This structure ensures that the risk profile is strictly defined by government-verified safety data.

Overdose and Emergency Response

Official Overdose Manifestations and Emergency Action

Regulatory documentation defines the overdose profile of Choline alfoscerate by the clinical manifestations associated with high exposure levels, which are consistent with excessive cholinergic activity. The documented acute symptoms include nausea, diarrhea, and a risk of hypotension (low blood pressure). These effects inform the Tolerable Upper Limit (UL) for related choline compounds.

Upon any suspicion of overdose, the official regulatory guidance requires immediate action: the user must immediately inform the treating doctor and seek assistance from a qualified professional as quickly as possible. This urgent help-seeking action is mandatory even if symptoms appear mild.

Management and Long-Term Risk

The management of a Cereton overdose relies on general clinical principles. No specific antidote is known or documented in the official prescribing information; therefore, the required procedure is symptomatic and supportive treatment. Furthermore, safety assessments note a serious long-term association: use of the compound is linked to an increased 10-year incident stroke risk, particularly in a dose-response manner, which is a critical consideration in cases of high or prolonged exposure. This risk profile contributes to the strict requirements for professional monitoring following a suspected overdose.

Therapeutic Uses of Cereton

What Cereton Treats: Main Uses and Benefits

Cereton is commonly used to help with symptomatic support in patients dealing with a range of neurological conditions that may compromise mental capacity, offering supportive therapeutic benefit across key functional domains. The active ingredient, Choline alfoscerate, is indicated for the management of symptoms related to cognition, behavior, and functional stability.

The medication is applicable across conditions characterized by symptoms that interfere with daily functioning, including Mild Cognitive Impairment (MCI), mild-to-moderate dementia (both Alzheimer's and vascular types), post-stroke sequelae, and post-traumatic cognitive impairment.

It is applied in clinical settings when symptom clusters become disruptive, such as memory loss, reduced concentration, persistent apathy, irritability, and disorientation. In these situations, the medication is intended to assist with easing the overall symptom load.

“This supportive therapy is applied to help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.”


Quick Fact: Relief for Cognitive and Behavioral Strain

Domain Supportive Benefit
Cognition Helps ease mental confusion and concentration deficits.
Recovery Contributes to a sense of stability during post-stroke phases.
Behavior May help manage apathy and emotional instability.

Regulatory References

  1. NIH Systematic Review on Alpha-GPC

Eligibility and Restrictions for Use

The eligibility for using Cereton (Choline alfoscerate) is strictly defined by regulatory guidelines, which establish populations for whom the medicine is permitted, restricted, or prohibited.

Contraindicated Populations

Use of Cereton is absolutely contraindicated for the following groups:

  • Patients with known hypersensitivity to Choline alfoscerate or any excipients.
  • Women who are pregnant or breastfeeding (lactation).

Age and Organ Function Restrictions

Population Group Regulatory Status Governing Wording
Adults and Older Adults Eligible (Use Established) Recommended for adults and elderly patients from 18 years old.
Pediatric (Under 18) Use Not Established Safety and efficacy have not yet been established in children below 18 years.
Renal/Hepatic Impairment Use Not Established Safety and efficacy have not yet been established in patients with renal or hepatic impairment.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing absolute prohibitions based on reproductive status and allergies, while confirming eligibility for adults. Use is not established in the pediatric population or in patients with pre-existing severe renal or hepatic impairment.

What should I know about interactions with other medicines?

The official interaction profile for Cereton (Choline alfoscerate) is defined by documented effects on the central nervous system's cholinergic system and specific constraints for the injectable form. Regulatory documents primarily identify interactions within two main domains:

Interaction Domain Relevant Interacting Substances/Classes
Pharmacodynamic Interference Anticholinergic Drugs (e.g., physostigmine, ipratropium bromide)
Cholinergic Agonists (e.g., muscarine, nicotine, acetylcholine)
Administration Incompatibility Heparin (Parenteral form only)

Co-administration with Anticholinergic Drugs may officially result in the reduction of the pharmacological effect of Cereton. Conversely, use with other Cholinergic Agonists may officially enhance the pharmacological effect. These interactions are classified based on interference with the same neurotransmitter pathway.

For the parenteral solution, a procedural restriction is necessary: the Cereton solution for injection is chemically incompatible with Heparin and must not be administered in the same syringe.

Regulatory labels do not document interactions involving drug transporters or major metabolic enzymes like the CYP450 system. Separately, official advisories note that the use of alcohol is associated with a potential for increased dizziness.

Mechanism of Action

Choline Donor and Acetylcholine Synthesis

The mechanism of Choline alfoscerate (Cereton) is defined by a dual action that begins with its enzymatic cleavage in the central nervous system. The drug functions as an efficient choline donor, supplying the essential substrate for the enzyme choline acetyltransferase (ChAT). This interaction increases the rate of acetylcholine (ACh) synthesis and release in central nervous system circuits, leading to an enhancement of cholinergic signaling and optimized central synaptic function.

Neuronal Membrane Structural Support

In parallel, the molecule's glycerophosphate component enters the phospholipid biosynthesis pathway, serving as a direct precursor for structural lipids. This mechanism provides metabolic support for the maintenance, repair, and functional fluidity of neuronal cell membranes. By supplying these essential building blocks, the drug supports neuronal viability and sustained membrane function within the CNS.

Dosage and Administration Information

The administration of Cereton (Choline alfoscerate) is defined by a two-part treatment protocol: an initial, short-term parenteral phase and a long-term oral maintenance phase. This phased approach governs both the route and the dosage.

The initial acute course is typically administered via the parenteral route, using intramuscular injection or slow intravenous infusion. The standard dose for this phase is 1000 mg administered once daily. If delivered intravenously, the solution must be diluted in a physiological solution prior to infusion and is typically performed under medical supervision. This acute phase generally lasts 10 to 15 days before transitioning to outpatient management.

The long-term maintenance phase utilizes the oral route, provided as 400 mg capsules or tablets. The standard total daily dose is 1200 mg, which is divided and taken as three separate doses daily. Standard protocols indicate that the oral form is typically taken before meals and must be swallowed whole; the tablets or capsules must not be chewed, crushed, or broken. The duration of the oral course typically extends for 3 to 6 months or more and may be repeated in cycles as part of a long-term strategy. No specific dose adjustments for adult patients are consistently detailed in general prescribing information for cases of hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cereton


Evidence for Mild-to-Moderate Alzheimer's Disease and Vascular Cognitive Impairment

Research examining Cereton (Choline alfoscerate) has primarily involved randomized controlled trials (RCTs) and systematic reviews in older adults with mild-to-moderate Alzheimer's Disease Dementia (ADD). Studies monitored cognitive function (e.g., MMSE, ADAS-Cog) and global clinical state over periods typically lasting six to twelve months. The research explored the compound's use alone (monotherapy) and in combination with other drugs used for dementia.

For Vascular Cognitive Impairment (VCI), studies monitored functional and cognitive outcomes over periods up to 48 weeks in patients with cognitive issues linked to cerebrovascular events. Reports from these trials describe the measurements and patterns observed in patient scores during the study periods, noting that the research scope applies only to stable populations and not those in the acute recovery phase.


Evidence for Mild Cognitive Impairment (MCI)

Research for Mild Cognitive Impairment (MCI) includes long-term observational studies that examined the association between the compound's use and the critical outcome of conversion to all-cause dementia. Shorter pilot RCTs have also tracked changes in cognitive scores and objective markers. Long-term observational data showed mixed patterns regarding the progression risk. Due to limited trial follow-up relative to the disease timeline and inconsistent real-world findings, the certainty remains low for this specific application.


Research Gaps and Uncertainty

The evidence quality varies across the existing studies, and many key trials are older. Follow-up durations are generally short, meaning long-term effects are not fully established based on controlled trials. Available evidence is often not directly comparable to that of newer pharmacological options. Furthermore, data for certain groups (e.g., younger adults or those with specific complex comorbidities) remain insufficient. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Comparison of the Effects of Choline Alphoscerate and Citicoline in Patients with Dementia Disorders: A Systematic Review and Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Cereton (FAQ)


Q: Is Cereton considered a long-term treatment?

A: Official documentation describes the treatment using a two-part protocol: a short initial phase followed by a long-term oral maintenance phase. The oral course is typically designed to extend for three to six months or more and may be repeated in cycles as part of a long-term strategy.

Q: Does Cereton cause weight gain or weight loss?

A: The officially documented adverse reactions for Cereton primarily involve the gastrointestinal and nervous systems. Changes in body weight, such as weight gain or weight loss, are not typically documented among the adverse effects listed in regulatory documents.

Q: Is feeling more energetic a common experience on Cereton?

A: Official adverse reaction documents do not include increased energy as a reported side effect. The adverse reaction profile does, however, include specific psychiatric and nervous system effects like Insomnia (difficulty sleeping) and Headache.

Q: Does Cereton affect blood pressure?

A: Official regulatory labels that describe the known adverse reaction profile do not specifically document changes in blood pressure or other cardiovascular effects.

Q: Is Cereton appropriate for people with liver problems?

A: Regulatory guidelines state that the safety and effectiveness of Cereton have not yet been established in people with pre-existing hepatic impairment (liver problems). Use is limited because specific information on safety and effectiveness has not been established in this population.

Q: Can Cereton be used by people with kidney disease?

A: Official guidelines indicate that the safety and effectiveness of Cereton have not yet been established for patients with pre-existing renal impairment (kidney disease). This indicates that official safety and effectiveness data have not been established for this population.

Q: Can people taking blood thinners also use Cereton?

A: The official interaction profile notes a procedural restriction: the injectable form of Cereton is chemically incompatible with Heparin and must not be administered in the same syringe. The oral form does not have documented interactions with non-Heparin blood thinners in core regulatory documents.

Q: How long does Cereton stay in the body after the last dose?

A: Official labels do not typically detail the exact pharmacokinetics, such as the drug's half-life. The drug's activity is related to increasing the body's concentration of choline, a naturally occurring substance that is processed by the body over time.

Q: Does Cereton interfere with birth control pills?

A: Official regulatory documents that describe known drug interactions do not document an interaction between Cereton and hormonal contraceptives (birth control pills).

Q: If Cereton is used for a long time, does its effect lessen?

A: Research has noted that long-term effects are not fully established based on available controlled trials. Observational data on the drug’s effects over extended periods have shown mixed patterns.

Q: Can I take Cereton if I am already taking over-the-counter pain relievers?

A: Official regulatory labels defining drug-to-drug interactions do not document specific interactions involving common over-the-counter pain relievers and Cereton.

Q: Is it safe to consume alcohol while using Cereton?

A: Official advisories note that the use of alcohol has been associated with a potential for increased dizziness.

Q: Can Cereton be taken with herbal supplements like St. John's Wort?

A: The core regulatory documents detailing drug interactions with Cereton do not specifically document interactions with St. John's Wort or other herbal supplements.

Q: Why do some people compare Cereton to other 'brain' medicines?

A: Cereton is formally classified by the World Health Organization's ATC system as an 'Other Parasympathomimetic.' It is also pharmacologically recognized as both a Nootropic agent and a Neuroprotector, which explains its association with other medicines intended to support central nervous system function.

Q: What is the difference between Cereton and other drugs that treat similar symptoms?

A: Cereton is described by its dual action mechanism: it functions as a donor of choline for acetylcholine synthesis, and its glycerophosphate component serves as a precursor for structural lipids in neuronal membranes. This dual action is the basis for its identity.

Q: Is it normal to feel a change in sleep patterns when taking Cereton?

A: The officially listed adverse reaction profile for Cereton includes Insomnia (difficulty sleeping). This indicates that changes in a person's sleep pattern are noted as a possible effect.

Q: Are there special considerations for taking Cereton if you have a heart condition?

A: Official regulatory documents and safety constraints focus on populations such as pregnant or breastfeeding women and those with severe kidney or liver impairment. Pre-existing heart conditions are not listed as a specific contraindication or special warning for Cereton use.

Q: Has Cereton been studied in children or adolescents?

A: Official regulatory documents explicitly state that the safety and effectiveness of Cereton have not yet been established in children and adolescents.

Q: How does Cereton affect mood or anxiety levels?

A: Studies have generally focused on the cognitive outcomes of Cereton. Some research has also examined the compound’s effect on non-cognitive symptoms, such as anxiety, noting findings related to group patterns in the studies.

Q: What is the typical duration of treatment with Cereton?

A: The long-term oral maintenance course for Cereton typically lasts for three to six months or more. This phase may be repeated in cycles, as defined by official prescribing strategies.

Q: If I have allergies, should I check any specific ingredient in Cereton?

A: Official regulatory guidelines state that use of Cereton is contraindicated (prohibited) for individuals with a known hypersensitivity or allergy to the active substance, Choline alfoscerate, or any of the inactive ingredients (excipients) in the product.

Q: Is Cereton known to affect vision?

A: Official regulatory labels that detail the known adverse reaction profile do not document any visual disturbances or other ophthalmological effects.

Q: Can Cereton be split or crushed to make it easier to swallow?

A: Official administration instructions state that the oral tablets or capsules must be swallowed whole. They are specified as not to be chewed, crushed, or broken.

Q: Are the safety standards for Cereton the same across different countries?

A: The drug's core safety profile is established by data on the active substance, Choline alfoscerate. This information is reviewed by major regulatory bodies globally, and the substance is internationally classified by the World Health Organization (WHO) ATC system.

Q: Is Cereton covered by most health insurance plans?

A: Coverage and reimbursement by specific health insurance plans are commercial or financial details that are not addressed in official drug regulatory documents.

How should Cereton be stored and disposed of?

How to Store and Dispose of Cereton?

Cereton (Choline alfoscerate) must be stored according to specific regulatory requirements to maintain its stability, which is sensitive to environmental factors.


Storage Requirements

  • Temperature: Store at a temperature not exceeding 25mathrmC.
  • Environmental Protection: The medicine must be actively protected from light and stored in a location that is cool and dry. Protection from ambient moisture is mandatory to prevent product degradation.
  • Child Safety: It is mandatory to store Cereton out of the sight and reach of children.

Disposal Instructions

Disposal must comply with official regulatory guidance for pharmaceutical waste:

  • Waste Handling: Unused or expired medication must be taken to an approved pharmaceutical waste disposal plant.
  • Environmental Restriction: Do not discharge Cereton into household wastewater, surface water, or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cereton found in:

A-Z Index: